The company is now up by 5.30% at $1.39 giving it a place as a top gainer in the market today. More than 744,224 shares have changed hands.
Recent news headlines for Regulus Therapeutics Inc..
Shares of the company are trading at $1.39 impressively higher than $1.01, the 50 day moving average and which is significantly higher than the 200 day moving average of $1.23. The 50 day moving average was up $0.38 or +38.17% and the 200 day average went up by +12.76%.
Traders are feeling more bearish on the company recently at least if you consider the rise in short interest. The firm recorded a rise in short interest of 32.66% as of August 31, 2017 from the last reporting period. Short interest increased 868,885 over that timeframe. The days to cover increased to 6.0 and the percentage of shorted shares is 0.07% as of August 31.
Regulus Therapeutics Inc. (NASDAQ:RGLS) has been the object of insider buying activity recently. Daniel R. Chevallard, CFO disclosed the purchase of 54,945 shares of (RGLS). The shares were bought on July 25th for an average price of $0.91. Chevallard now owns $54,068 of the stock per the Form 4 SEC filing. Joseph P. Hagan, President and CEO purchased $200,000 worth of shares at an average price of $0.91 on Tue the 25th. The President and CEO now owns $219,580 of the stock as reported to the SEC.
Director Stelios Papadopoulos bought 1,000,000 shares at an average price of $0.91 on July 25th. That brings Papadopoulos’s holdings to $1,611,316 per an SEC filing yesterday.
These funds have shifted positions in (RGLS). Ubs Group Ag cut its ownership by selling 5,869 shares a decrease of 94.8%. Ubs Group Ag now holds 324 shares valued at $0. The total value of its holdings decreased 100.0%. As of the end of the quarter Ecor1 Capital, LLC had bought a total of 2,199,144 shares growing its stake by 145.6%. The value of the total investment in Regulus Therapeutics Inc. increased from $2,492,000 to $3,656,000 a change of 46.7% quarter over quarter.
As of quarter end Creative Planning had disposed of 15,000 shares trimming its position 93.8%. The value of the company’s investment in Regulus Therapeutics Inc. went from $26,000 to $1,000 decreasing 96.2% for the reporting period. Gsa Capital Partners Llp added to its position by buying 126,324 shares an increase of 877.8% in the quarter. Gsa Capital Partners Llp owns 140,715 shares worth $139,000. The value of the position overall is up by 39.0%.
On August 2 the company was downgraded from “Buy” to “Neutral” in a statement from Chardan Capital.
As of the latest earnings report the EPS was $-1.53 and is expected to be $-1.02 for the current year with 103,785,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.18 with next year’s EPS anticipated to be $-0.53.
Regulus Therapeutics Inc., launched on September 5, 2007, is a biopharmaceutical company focused on discovering and developing drugs that target microribonucleic acid (microRNAs) to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Business’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations..